Back to Search
REHAM GAAFAR MD
MD
Family Medicine Physician
NPI: 1760126130IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
35.154042(OH)
Education
OTHER
Class of 2021
Research & Publications (19)
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
PMID 19502050·Eur J Cancer·2009
8-other
Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
PMID 18640302·Ann Thorac Surg·2008
8-other
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
PMID 18089874·J Clin Oncol·2007
3-trial
Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma.
PMID 17610473·Pathol Int·2007
8-other
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
PMID 16446322·J Clin Oncol·2006
3-trial
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.
PMID 16968876·Ann Oncol·2006
2-rct
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
PMID 16549997·Anticancer Drugs·2006
3-trial
Bacterial artificial chromosome-derived molecular markers for early bolting in sugar beet.
PMID 15714328·Theor Appl Genet·2005
4-observational
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
PMID 16192580·J Clin Oncol·2005
3-trial
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: National Cancer Institute Cairo experience.
PMID 15716991·J Egypt Natl Canc Inst·2004
8-other
Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR.
PMID 14734470·Clin Cancer Res·2004
4-observational
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
PMID 14581415·J Clin Oncol·2003
3-trial
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions.
PMID 12881386·Ann Oncol·2003
4-observational
A bacterial artificial chromosome (BAC) library of sugar beet and a physical map of the region encompassing the bolting gene B.
PMID 12715161·Mol Genet Genomics·2003
8-other
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
PMID 12538462·Clin Cancer Res·2003
3-trial
Breast cancer in Egypt: a review of disease presentation and detection strategies.
PMID 15751939·East Mediterr Health J·2003
6-review
A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.
PMID 10908847·Eur J Cancer·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6540 WINTON RD
CINCINNATI, OH 45224 - Phone
- (513) 981-4180
Quick Facts
- NPI
- 1760126130
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 5
- Publications
- 19
Are you this provider?
Claim Your Profile